
Michael W O'reilly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6754261/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adrenal insufficiency is common amongst kidney transplant recipients receiving maintenance prednisolone and can be predicted using morning cortisol. Nephrology Dialysis Transplantation, 2023, 38, 236-245.	0.7	4
2	Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors. Annals of Internal Medicine, 2022, 175, 325-334.	3.9	53
3	Approach to androgen excess in women: Clinical and biochemical insights. Clinical Endocrinology, 2022, 97, 174-186.	2.4	26
4	Approach to the Patient: Hyponatremia and the Syndrome of Inappropriate Antidiuresis (SIAD). Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2362-2376.	3.6	9
5	Cardiometabolic and psychological effects of dual-release hydrocortisone: a cross-over study. European Journal of Endocrinology, 2021, 184, 253-265.	3.7	13
6	Growth Hormone/Insulin Growth Factor Axis in Sex Steroid Associated Disorders and Related Cancers. Frontiers in Cell and Developmental Biology, 2021, 9, 630503.	3.7	16
7	Increased COVID-19 infections in women with polycystic ovary syndrome: a population-based study. European Journal of Endocrinology, 2021, 184, 637-645.	3.7	65
8	Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study. Diabetes Care, 2021, 44, 2758-2766.	8.6	4
9	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology,the, 2020, 8, 773-781.	11.4	129
10	Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882093431.	3.2	25
11	Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess. Annals of Internal Medicine, 2019, 171, 107.	3.9	145
12	Serum testosterone, sex hormoneâ€binding globulin and sexâ€specific risk of incident type 2 diabetes in a retrospective primary care cohort. Clinical Endocrinology, 2019, 90, 145-154.	2.4	42
13	A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. JCI Insight, 2019, 4, .	5.0	55
14	Increased risk of obstructive sleep apnoea in women with polycystic ovary syndrome: a population-based cohort study. European Journal of Endocrinology, 2019, 180, 265-272.	3.7	40
15	Causes, patterns and severity of androgen excess in 487 consecutively recruited pre- and post-pubertal children. European Journal of Endocrinology, 2019, 180, 213-221.	3.7	22
16	OR29-2 Mild Autonomous Cortisol Excess (MACE) in Adrenal Incidentalomas - Metabolic Risk Profile and Urinary Steroid Metabolome Analysis in 1208 Prospectively Recruited Patients. Journal of the Endocrine Society, 2019, 3, .	0.2	0
17	MON-203 Local Activation of 11-Oxygenated Androgens by AKR1C3 Is the Predominant Source of Androgens in Human Female Adipose Tissue. Journal of the Endocrine Society, 2019, 3, .	0.2	0
18	SAT-368 Natural History Of Adrenal Incidentalomas With And Without Mild Autonomous Cortisol Excess; A Systematic Review And Meta-analysis. Journal of the Endocrine Society, 2019, 3, .	0.2	1

MICHAEL W O'REILLY

#	Article	IF	CITATIONS
19	Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1214-1223.	3.6	50
20	Evaluating the Fat Distribution in Idiopathic Intracranial Hypertension Using Dual-Energy X-ray Absorptiometry Scanning. Neuro-Ophthalmology, 2018, 42, 99-104.	1.0	42
21	Metabolic Concepts in Idiopathic Intracranial Hypertension and Their Potential for Therapeutic Intervention. Journal of Neuro-Ophthalmology, 2018, 38, 522-530.	0.8	78
22	Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. PLoS Medicine, 2018, 15, e1002542.	8.4	119
23	Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1889-1897.	3.6	68
24	11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 840-848.	3.6	192
25	MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease. European Journal of Endocrinology, 2017, 177, R125-R143.	3.7	105
26	What Do Transgender Patients Teach Us About Idiopathic Intracranial Hypertension?. Neuro-Ophthalmology, 2017, 41, 326-329.	1.0	35
27	AKR1C3-Mediated Adipose Androgen Generation Drives Lipotoxicity in Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3327-3339.	3.6	133
28	Acute Hypercortisolemia Exerts Depot-Specific Effects on Abdominal and Femoral Adipose Tissue Function. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1091-1101.	3.6	8
29	ACTH and gonadotropin deficiencies predict mortality in patients treated for nonfunctioning pituitary adenoma: longâ€ŧerm followâ€ʉp of 519 patients in two large European centres. Clinical Endocrinology, 2016, 85, 748-756.	2.4	46
30	Advanced nonâ€alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alström syndrome. Liver International, 2016, 36, 1704-1712.	3.9	23
31	CHARACTERISING FAT DISTRIBUTION AND RESPONSE TO WEIGHT LOSS IN IIH. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.208-e1.	1.9	0
32	SFRP2 Is Associated with Increased Adiposity and VEGF Expression. PLoS ONE, 2016, 11, e0163777.	2.5	27
33	Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome. Lancet, The, 2015, 385, S16.	13.7	43
34	PAPSS2 Deficiency Causes Androgen Excess via Impaired DHEA Sulfation—In Vitro and in Vivo Studies in a Family Harboring Two Novel PAPSS2 Mutations. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E672-E680.	3.6	62
35	Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1027-1036.	3.6	231
36	Understanding androgen action in adipose tissue. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 277-284.	2.5	120

MICHAEL W O'REILLY

#	ARTICLE	IF	CITATIONS
37	A comparative quality assessment of evidenceâ€based clinical guidelines in endocrinology. Clinical Endocrinology, 2013, 78, 183-190.	2.4	35
38	ATLANTIC-DIP: Raised Maternal Body Mass Index (BMI) Adversely Affects Maternal and Fetal Outcomes in Glucose-Tolerant Women According to International Association of Diabetes and Pregnancy Study Groups (IADPSG) Criteria. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E608-E612.	3.6	53
39	Atlantic DIP: high prevalence of abnormal glucose tolerance post partum is reduced by breast-feeding in women with prior gestational diabetes mellitus. European Journal of Endocrinology, 2011, 165, 953-959.	3.7	88
40	Rho A/Rho kinase: human umbilical artery mRNA expression in normal and pre eclamptic pregnancies and functional role in isoprostane-induced vasoconstriction. Reproduction, 2006, 132, 169-176.	2.6	21
41	Specific PGF _{2α} receptor (FP) antagonism and human uterine contractility <i>in vitro</i> . BJOC: an International Journal of Obstetrics and Gynaecology, 2005, 112, 1034-1042.	2.3	23
42	Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro. Reproductive Biology and Endocrinology, 2004, 2, 80.	3.3	28
43	Improving Door-to-Drug time and ST segment resolution in AMI by moving thrombolysis administration to the Emergency Department. International Emergency Nursing, 2004, 12, 2-9.	0.7	15